Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Acta Diabetologica
Published in: Acta Diabetologica 2/2021

01-02-2021 | Sitagliptin | Letter to the Editor

Use of DPP-4 inhibitors in patients with COVID-19

Authors: Chia Siang Kow, Syed Shahzad Hasan

Published in: Acta Diabetologica | Issue 2/2021

Login to get access

Excerpt

We read with interest the discussion by Solerte et al. [1] on the various physiological processes on the immune system where dipeptidyl peptidase‐4 (DPP‐4) is involved. Besides, as hypothesized by the authors, the presence of DPP-4 in the respiratory tract may facilitate the entry of severe acute respiratory syndrome (SARS-CoV-2), the causative pathogen for coronavirus disease 2019 (COVID-19). Therefore, at first sight, it seems logical for the authors to propose that the use of DPP-4 inhibitors may be benficial in patients with COVID-19. …
Literature
1.
Solerte SB, Di Sabatino A, Galli M, Fiorina P (2020) Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19 Acta Diabetol 57:779–783.
2.
Hasan SS, Radford S, Kow CS, Zaidi STR (2020) Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review and meta-analysis [published online ahead of print, 2020 Aug 3]. J Thromb Thrombolysis 1–8.
3.
Maier CL, Truong AD, Auld SC, Polly DM, Tanksley CL, Duncan A (2020) COVID-19-associated hyperviscosity: a link between inflammation and thrombophilia? Lancet 395:1758–1759CrossRef
4.
Krijnen PA, Hahn NE, Kholová I et al (2012) Loss of DPP4 activity is related to a prothrombogenic status of endothelial cells: implications for the coronary microvasculature of myocardial infarction patients. Basic Res Cardiol 107:233CrossRef
5.
Gouverneur A, Lair A, Arnaud M et al (2020) DPP-4 inhibitors and venous thromboembolism: an analysis of the WHO spontaneous reporting database. Lancet Diabetes Endocrinol 8:365–367CrossRef
Metadata
Title
Use of DPP-4 inhibitors in patients with COVID-19
Authors
Chia Siang Kow
Syed Shahzad Hasan
Publication date
01-02-2021
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 2/2021
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-020-01629-y

Other articles of this Issue 2/2021

Acta Diabetologica 2/2021 Go to the issue

Correction

Correction to: Maternal diabetes and risk of childhood malignancies in the offspring: a systematic review and meta‑analysis of observational studies

Review Article

Left atrial function in diabetes: does it help?

Short Communication

Increased fecal indole concentration in women with gestational diabetes: a pilot study

Original Article

Different retinopathy phenotypes in type 2 diabetes predict retinopathy progression

Original Article

Type 1 diabetes outcomes of children born in Israel of Eritrean asylum seekers

Original Article

Predictions of diabetes complications and mortality using hba1c variability: a 10-year observational cohort study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits